PhRMA· @PhRMA · X·· 19 小时前AI 评分20
AI 导读
中国将生物医药列为国家战略重点,如今正产出一些全球最有前景的科学成果。但中国的科学增多,并不意味着美国的科学减少。 美国 Phase 1 临床试验数量有所增加,美国生物技术仍是资本投资的磁石。 继续阅读:https://ow.ly/wjrp5107vBE
正文
China made biopharma a national strategic priority and is now producing some of the world's most promising science. But more science in China doesn’t mean less science in America.
U.S. Phase 1 clinical trials have increased and U.S. biotech remains a magnet for capital investment.
Keep reading: https://ow.ly/wjrp5107vBE
来源:PhRMA · x.com